Home All Topics Ordering Prescribing Made Easy

Prescribing Made Easy

Prescribing Made Easy

Fensolvi Total Solutions

Start by enrolling your patient in Fensolvi Total Solutions

1 (866)-FENSOLVI (336-7658)
Monday – Friday, 9:00am to 8:00pm EST, Saturday 11:00am to 3:00pm EST
Download the Fensolvi TotalSoutions Patient Enrollment Form

Dedicated patient and office support will make the treatment process as simple as possible for you, your patients and their families.

Quick turnaround time

The innovative portal means an average turnaround time of 4 hours for benefit investigations, including both pharmacy and medical claims.

Simplicity

Fensolvi TotalSolutions keeps things simple for your practice, your patients, and their parents.

Full support

We offer a full line of patient support services, including

Office support
  • Patient enrollment services
  • Benefit verification
  • Billing & coding questions
  • Case management
  • Prior authorization and appeals assistance
Patient support
  • Patient enrollment services
  • Benefit investigation
  • Patient education materials
Adherence support

Support provided to patients who elect to receive additional communications and materials to help with their treatment journey

Financial support

  • Copay assistance program

    • zoom

      Copay assistance is available for your eligible patients, allowing them to pay as little as $5 for their Fensolvi® Prescription

  • Patient assistance program (PAP)

IMPORTANT SAFETY INFORMATION

Expand Minimize

FENSOLVI (leuprolide acetate) for injectable suspension is a gonadotropin releasing hormone (GnRH) agonist used to treat patients 2 years of age and older with central precocious puberty (CPP). CPP may be diagnosed when signs of sexual maturity begin to develop in girls under the age of 8 or in boys under the age of 9.

FENSOLVI is contraindicated in individuals with hypersensitivity to any drug that is in the same class as FENSOLVI, in individuals who are allergic to any of the ingredients in FENSOLVI, or in individuals who are pregnant. FENSOLVI may cause fetal harm when administered to a pregnant patient.

During the first few weeks of treatment, increases in gonadotropins and sex steroids above baseline may result in an increase in signs and symptoms of puberty including vaginal bleeding in girls.

Psychiatric events have been reported in patients taking GnRH agonists. Events include emotional lability, such as crying, irritability, impatience, anger, and aggression. Patients should be monitored for development or worsening of psychiatric symptoms.

Convulsions have been observed in patients treated with GnRH agonists with or without a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and in patients on concomitant medications that have been associated with convulsions such as bupropion and SSRIs.

Pseudotumor Cerebri (Idiopathic Intracranial Hypertension) has been reported in pediatric patients treated with GnRH agonists.  Patients should be monitored for headache, papilledema and blurred vision.

The most common adverse events seen with FENSOLVI were: injection site pain, nasopharyngitis, pyrexia, headache, cough, abdominal pain, injection site erythema, nausea, constipation, vomiting, upper respiratory tract infection, bronchospasm, productive cough and hot flush. 

Please see Full Prescribing Information for FENSOLVI for additional important safety information. 

To report suspected adverse reactions contact Tolmar at 1-844-4TOLMAR (486-5627) or the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.